Elgart G W, Sheremata W, Ahn Y S
Department of Dermatology, University of Miami School of Medicine, FL 33136, USA.
J Am Acad Dermatol. 1997 Oct;37(4):553-8. doi: 10.1016/s0190-9622(97)70170-1.
Recombinant human interferon beta-1b has been recently approved for the treatment of multiple sclerosis. A significant proportion of patients treated with this medication experienced cutaneous reactions.
We describe the clinical and histologic features of cutaneous reactions to recombinant human interferon beta-1b.
Consecutive patients with cutaneous reactions to recombinant interferon beta-1b were evaluated clinically and by biopsy.
Clinical lesions varied from subtle uninflamed sclerotic dermal plaques to erythematous plaques to cutaneous ulcers at injection sites. The nonsclerotic lesions were frequently painful. The firm plaques showed fibrosis histologically, whereas nonsclerotic inflammatory lesions demonstrated a consistent pattern of vascular thrombosis. Hematologic evaluation demonstrated platelet activation in most patients with inflammatory lesions, a feature also noted before interferon treatment in some patients.
Therapy with recombinant interferon beta-1b is associated with a spectrum of cutaneous reactions and vascular thrombosis.
重组人干扰素β-1b最近已被批准用于治疗多发性硬化症。接受这种药物治疗的患者中有很大一部分出现了皮肤反应。
我们描述了重组人干扰素β-1b皮肤反应的临床和组织学特征。
对连续出现重组干扰素β-1b皮肤反应的患者进行临床评估和活检。
临床病变从注射部位细微的无炎症硬化性真皮斑块到红斑性斑块再到皮肤溃疡不等。非硬化性病变通常疼痛。坚硬的斑块在组织学上显示纤维化，而非硬化性炎症病变则呈现一致的血管血栓形成模式。血液学评估显示，大多数有炎症病变的患者存在血小板活化，这一特征在一些患者干扰素治疗前也有发现。
重组干扰素β-1b治疗与一系列皮肤反应和血管血栓形成有关。
